Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kerecis Omega3 Viruxide is a **medical device based virucidal and bactericidal lipid system** developed by Kerecis for wound care and mucosal infection control applications. It is described as containing patented fatty acids derived from fish and plants, with neem oil and St. John's Wort oil identified as key active components, and has been incorporated into products such as wound spray and oral or nasal spray formulations. Rather than acting as a conventional single target pharmaceutical, the system is intended to reduce microbial and viral load at the site of application, support local barrier protection, and lessen infection related symptoms; it was also evaluated clinically as an oral and intranasal spray approach for COVID-19 to help prevent disease progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kerecis Omega3 Viruxide.